Heterogeneity in Alzheimer Disease Progression Affects Clinical Trial Results
Investigators assessed the variability in effect of treatment over time among patients with mild cognitive impairment or dementia.
Investigators assessed the variability in effect of treatment over time among patients with mild cognitive impairment or dementia.
High body weight variability may be associated with increased risk for all-cause dementia and Alzheimer dementia in older patients.
Pimavanserin, either alone or in conjunction with a selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor, may improve comorbid depression symptoms in patients with Parkinson disease.
Closer adherence to the alternative Mediterranean diet is associated with a reduced risk for cognitive decline, but not with slower decline in cognitive function.
Using the Visual Association Test along with the Mini Mental State Examination may improve predictive value to screen for cognitive deficits.
Longitudinal associations between diabetes and cognitive decline have been reported.
Providing healthy eating and adequate nutrients to a baby during their first 1000 days is important for optimal neurodevelopment.
Slower cognitive decline is linked with intake of primary nutrients and bioactives in leafy green vegetables.
There is a strong link between CTE and American football.
In bipolar disorder, neurocognitive impairment needs to be considered a therapeutic clinical target to improve psychosocial functioning.